29 January 2025
: Case report 
Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Clinical situation which can not be reproduced for ethical reasons
Fatmawati Kamal
1ABCDEF*, Halimatun Radziah Othman2ABCDEF
DOI: 10.12659/AJCR.945579
Am J Case Rep 2025; 26:e945579
Table 5. PT and INR results at the satellite laboratory.
| Date | PT | INR | Anticoagulant | ||
|---|---|---|---|---|---|
| Coagulation analyzer = Stago STACompact MaxPT reagent= STA-NeoPTimal | Reference range | 12.0–14.0 | <1.2 | ||
| 2.3.2022 | 16.2 | 1.2 | No warfarin | ||
| 9.3.2022 | 31.3 | 2.5 | Warfarin 3 mg OD | ||
| 15.3.2022 | 22.5 | 1.7 | Warfarin 3.5 mg OD | ||
| Coagulation analyzer = Sysmex CS-2500PT reagent= Siemens Thromborel S | Reference range | 10.5–12.0 | <1.2 | ||
| 14.4.2022 | 21.8 | 1.9 | Warfarin 3.5 mg OD | ||
| 12.5.2022 | 27.7 | 2.5 |